Company intelligence / Profile preview

Accentia Biopharmaceuticals

Tampa, Florida, United Statescellculturecompany.com ↗

Ownership: Private
Development stage: Phase 3

Overview

The company had two lead products in Phase 3 clinical trials: SinuNase for chronic sinusitis and BiovaxID for follicular non-Hodgkin's lymphoma. Both products received Fast Track designation from the FDA. Additionally, their Revimmune product received Orphan Drug Status for prevention of GVHD following bone marrow transplantation.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Biologicsvaccinesanti-fungals
Industry: Biotech

Drug pipeline

2 assets

SinuNase

1 more asset in the full pipeline.

Request access →

Partnerships

Mayo Foundation for Medical Education and ResearchNational Cancer Institute

Beyond the preview

Go deeper on Accentia Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accentia Biopharmaceuticals.

Explore the full profile